positive
1h agoTorrent Pharma posts 30% Q2 profit rise backed by strong India and US market sales

Torrent Pharmaceuticals reported a 30% increase in Q2 profit to ₹591 crore, supported by robust sales momentum in India and revived traction in its US generics portfolio. Revenue grew 10% year-on-year to ₹3,302 crore, driven by chronic therapy demand, new product launches, and steady growth in branded formulations. Analysts noted that improved operating leverage and disciplined cost structures helped expand margins. The company highlighted continued investment in manufacturing capacity and R&D pipelines, reinforcing multi-market growth visibility for the upcoming quarters.
positive
1h agoTorrent Pharma posts 30% Q2 profit rise backed by strong India and US market sales

Torrent Pharmaceuticals reported a 30% increase in Q2 profit to ₹591 crore, supported by robust sales momentum in India and revived traction in its US generics portfolio. Revenue grew 10% year-on-year to ₹3,302 crore, driven by chronic therapy demand, new product launches, and steady growth in branded formulations. Analysts noted that improved operating leverage and disciplined cost structures helped expand margins. The company highlighted continued investment in manufacturing capacity and R&D pipelines, reinforcing multi-market growth visibility for the upcoming quarters.
about 1 hour ago
1 min read
80 words

Torrent Pharma reported a 30% rise in Q2 profit to ₹591 crore with revenue at ₹3,302 crore driven by strong India and US sales momentum.
Torrent Pharmaceuticals reported a 30% increase in Q2 profit to ₹591 crore, supported by robust sales momentum in India and revived traction in its US generics portfolio. Revenue grew 10% year-on-year to ₹3,302 crore, driven by chronic therapy demand, new product launches, and steady growth in branded formulations. Analysts noted that improved operating leverage and disciplined cost structures helped expand margins. The company highlighted continued investment in manufacturing capacity and R&D pipelines, reinforcing multi-market growth visibility for the upcoming quarters.

Torrent Pharmaceuticals reported a 30% increase in Q2 profit to ₹591 crore, supported by robust sales momentum in India and revived traction in its US generics portfolio. Revenue grew 10% year-on-year to ₹3,302 crore, driven by chronic therapy demand, new product launches, and steady growth in branded formulations. Analysts noted that improved operating leverage and disciplined cost structures helped expand margins. The company highlighted continued investment in manufacturing capacity and R&D pipelines, reinforcing multi-market growth visibility for the upcoming quarters.
Companies:
Torrent Pharmaceuticals
Tags:
stocks
earnings
stocks
earnings
pharma
torrent
Nov 13, 2025 • 19:31 IST